Longmont, Colo.-based Acertara Acoustic Laboratories—an independent ISO/IEC 17025:2017 accredited medical ultrasound acoustic measurement, testing, and calibration laboratory, and ISO 13485:2016 certified probe repair and new product development facility—announces that its research and development (R&D) team has recently been awarded U.S. patent No.10,760,949 related to a novel acoustic field analysis method used for testing diagnostic ultrasound probes for various performance failures, including dead elements.
The Acertara inventors for this patent are Dr. Nicholas Ellens, Acertara President and COO Levi Moore, and James Gessert.
Commenting on the new patent, Acertara CEO G. Wayne Moore says, “This patent represents the 28th patent our R&D team has been awarded related to diagnostic ultrasound system and probe testing devices. Our engineering team first developed the modern ultrasound probe testing paradigm more than 20 years ago when we introduced FirstCall at Sonora Medical Systems. It is our passion to continue redesigning the probe testing market by creating disruptive technologies that match the very complex and sophisticated ultrasound probes being used today, including 2D matrix arrays, single crystal arrays, pMUT arrays, and cMUT arrays.”
What’s more, he says, “Our team is focused on the continuing challenge of taking our test equipment and product development legacy to the next level by creating products that ensure the safety and efficacy of ultrasound probes and systems for our most important customers: patients. We have already made significant strides in that area by our introduction of the Aureon and ATLAS devices, both of which have patents issued, as well as multiple patents pending.”
The research and development team at Acertara Acoustic Laboratories has been awarded more than 40 U.S. and international medical device patents, ranging from 3D ultrasound and complex test devices, to devices that deliver super-saturated levels of oxygen, to myocardial tissue of heart attack patients.